Cover Image

Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer

Show other versions (1)

Purpose: The use of circulating tumor cells (CTC) as a prognostic marker in metastatic breast cancer (MBC) has been well established. However, their efficacy and accuracy are still under scrutiny mainly because of methods of their enrichment and identification. We hypothesized that circulating miRNA...

Full description

Saved in:
Bibliographic Details
Main Authors: Madhavan, Dharanija (Author) , Wallwiener, Markus (Author) , Cuk, Katarina (Author) , Modugno, Caroline (Author) , Scharpff, Martina (Author) , Schott, Sarah (Author) , Heil, Jörg (Author) , Turchinovich, Andrey (Author) , Yang, Rongxi (Author) , Benner, Axel (Author) , Trumpp, Andreas (Author) , Sohn, Christof (Author) , Schneeweiss, Andreas (Author) , Burwinkel, Barbara (Author)
Format: Article (Journal)
Language:English
Published: September 4, 2012
In: Clinical cancer research
Year: 2012, Volume: 18, Issue: 21, Pages: 5972-5982
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-12-1407
Online Access:Verlag, Volltext: http://dx.doi.org/10.1158/1078-0432.CCR-12-1407
Verlag, Volltext: http://clincancerres.aacrjournals.org/content/18/21/5972
Get full text
Author Notes:Dharanija Madhavan, Manuela Zucknick, Markus Wallwiener, Katarina Cuk, Caroline Modugno, Martina Scharpff, Sarah Schott, Jörg Heil, Andrey Turchinovich, Rongxi Yang, Axel Benner, Sabine Riethdorf, Andreas Trumpp, Christof Sohn, Klaus Pantel, Andreas Schneeweiss, and Barbara Burwinkel
Description
Summary:Purpose: The use of circulating tumor cells (CTC) as a prognostic marker in metastatic breast cancer (MBC) has been well established. However, their efficacy and accuracy are still under scrutiny mainly because of methods of their enrichment and identification. We hypothesized that circulating miRNAs can predict the CTC status of patients with MBC, and tested for the same. Furthermore, we aimed at establishing a panel of circulating miRNAs capable of differentiating MBC cases from healthy controls. Experimental Design: Circulating miRNAs from plasma of CTC-positive and CTC-negative patients with MBC, and healthy controls, were profiled by TaqMan Human MicroRNA arrays. Candidates from the initial screen were validated in an extended cohort of 269 individuals (61 CTC-positive, 72 CTC-negative, 60 CTC-low MBC cases, and 76 controls). Results: CTC-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375, and miR-801 than CTC-negative MBC and controls (P < 0.00001), whereas miR-768-3p was present in lower amounts in MBC cases (P < 0.05). miR-200b was singled out as the best marker for distinguishing CTC-positive from CTC-negative patients (AUC 0.88). We identified combinations of miRNAs for differentiating MBC cases from controls (AUC 0.95 for CTC-positive; AUC 0.78 for CTC-negative). Combinations of miRNAs and miR-200b alone were found to be promising prognostic marker for progression-free and overall survival. Conclusion: This is the first study to document the capacity of circulating miRNAs to indicate CTC status and their potential as prognostic markers in patients with MBC. Clin Cancer Res; 18(21); 5972-82. ©2012 AACR.
Item Description:Published online first September 4, 2012
Gesehen am 01.08.2018
Physical Description:Online Resource
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-12-1407

Similar Items